MAP
VKTX icon

Moody Aldrich Partners’s Viking Therapeutics VKTX Stock Holding History

Moody Aldrich Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,465
Closed -$1.3M – 218
2024
Q2 		$1.3M Sell
24,465
-31,270
-56% -$2.05M 0.25% 111
2024
Q1 		$4.57M Buy
+55,735
New +$2.48M 0.78% 58
2023
Q3 		– Sell
-194,470
Closed -$3.15M – 215
2023
Q2 		$3.15M Sell
194,470
-9,356
-5% -$196K 0.61% 68
2023
Q1 		$3.39M Buy
203,826
+907
+0.4% +$9.37K 0.69% 61
2022
Q4 		$1.91M Buy
+202,919
New +$906K 0.39% 86

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Moody Aldrich Partners's VKTX Position: Q3 2024 in Review

Moody Aldrich Partners sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 24,465 shares — an estimated $1.3M sold.

Moody Aldrich Partners first reported a position in VKTX in Q4 2022 and held it in 5 quarters. The position peaked at $4.57M in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Moody Aldrich Partners reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 24,465 Viking Therapeutics shares in Q3 2024, an estimated $1.3M.
  • Moody Aldrich Partners first reported a position in Viking Therapeutics in Q4 2022 and held it in 5 quarters.
  • Moody Aldrich Partners's Viking Therapeutics position peaked at $4.57M in Q1 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Moody Aldrich Partners's 13F filing for Q3 2024, filed 22 Oct 2024.